Theme watch · maturing
medtech stocks to watch · July 2026
As of 2026-07-29
Post-Colfax orthopedic pure-play turnaround: LimaCorporate integration plus FCF-conversion recovery (43% in 2024 toward a 70–80% target) is the…
De-levering small-cap orthobiologics turnaround, now maturing: the July-2025 refi killed the 2026 debt wall, margins inflected above 20%, and the…
Multi-year Medicare overhang lifted: finalized MolDX LCD (2026-07-16, effective 2026-08-30) affirms surveillance dd-cfDNA coverage for…
Sell-side discovery leg is spent: three Strong Buys with a $30.67 average against $28.68 (2026-07-17) leaves ~7% to consensus. The July 13 warrant…
Deal-rumor re-rate has already run: $13.79 (Jun 26) to $17.38 (Jul 17), +75% off the $9.92 low, on an unsigned ~$1.5B point-of-care divestiture.…
Stalled single-cell franchise re-rating on the spatial/multiomics pivot: Atera (ships H2 2026), Proteintech protein capability, and a Cleveland…
"3-mo price move" is the stock's market price change, not an orbyd return.
How this page is built
These are the names orbyd covers in the medtech stocks cluster — each with a dated research dossier. Names currently on the move rank first by 3-month price momentum, then the rest of the covered roster. Cluster membership is assigned by a frontier model, currently read as maturing.
New cluster of device and life-science-tools names carried by 3m strength (TXG 107.5, CDNA 62.9, PLSE 55.6) where 1m contributions are positive but far below 3m for five of seven the move is largely behind them. Only ATRC has a dated fundamental catalyst: Q2 adj EPS $0.18 vs $0.00 est, sales $153.6M vs $151.8M est and raised FY2026 GAAP EPS guidance to $0.05-$0.13 (7/23), with UBS keeping Buy but lowering to $50 (7/28). ACCELERATING requires new prints confirming the tools recovery; SATURATED if 1m contributions keep converging toward zero.
Questions
- What medtech stocks does orbyd cover?
- As of 2026-07-29, the medtech stocks orbyd tracks are led by ENOV, BVS, CDNA, PLSE, each with a dated research dossier. Names already moving rank first by 3-month price momentum; this is research, not a recommendation.
- Is the medtech stocks theme accelerating or slowing?
- orbyd's model reads this cluster as maturing as of 2026-07-29. New cluster of device and life-science-tools names carried by 3m strength (TXG 107.5, CDNA 62.9, PLSE 55.6) where 1m contributions are positive but far below 3m for five of seven the move is largely behind them. Only ATRC has a dated fundamental catalyst: Q2 adj EPS $0.18 vs $0.00 est, sales $153.6M vs $151.8M est and raised FY2026 GAAP EPS guidance to $0.05-$0.13 (7/23), with UBS keeping Buy but lowering to $50 (7/28). ACCELERATING requires new prints confirming the tools recovery; SATURATED if 1m contributions keep converging toward zero.
- How does orbyd rank medtech stocks?
- Every name links to its dated research dossier. Those currently on the move rank first by cross-sectional 3-month price momentum, then the rest of the covered roster by conviction. Methodology is open; this is research, not advice.
Related
As of 2026-07-29 · research, not advice.